John is President and CEO of Disc Medicine. Previously, John spent more than thirteen years building Acceleron from a privately-held startup to a public biotech (acquired by Merck & Co. for $11.5 billion in 2021). At Acceleron, John served in various roles including General Counsel, SVP of Corporate Development and finally EVP and Chief Business Officer. John led the repurposing and in-licensing of sotatercept for pulmonary hypertension from Bristol-Myers Squibb. Prior to Acceleron, John worked at Ropes & Gray and Foley Hoag. He received his undergraduate degree from Harvard College, summa cum laude, MSc from Stanford University, PhD from MIT in Biological Sciences, and JD from Harvard Law School.